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Heart failureis oneofthe mostcommonchronic medicalconditionsin thedeveloped world. Itis characterized by neurohormonal
activation of multiple systems that can lead to clinical deterioration and signiﬁcant morbidity and mortality. In this regard,
hyponatremia is due to inappropriate and continued vasopressin activity despite hypoosmolality and volume overload.
Hyponatremia is also due to diuretic use in an attempt to manage volume overload. When hyponatremia occurs, it is a marker
of heart failure severity and identiﬁes patients with increased mortality. The recent introduction of speciﬁc vasopressin-receptor
antagonists oﬀers a targeted pharmacological approach to these pathophysiological derangements. Thus far, clinical trials with
vasopressin-receptor antagonists have demonstrated an increase in free-water excretion, improvement in serum sodium, modest
improvements in dyspnea but no improvement in mortality. Continued clinical trials with these agents are needed to determine
their speciﬁc role in the treatment of both chronic and decompensated heart failure.
1.Introduction
Heart failure (HF) is an increasingly common condition,
with recent American data revealing a 1 in 5 lifetime risk for
both sexes, and over 5 million currently aﬀected patients
[1]. In addition to being common, morbidity and mortality
attributable to HF continue to rise with over 1.1 million
hospital discharges and 1 in 8 death certiﬁcates mentioning
heart failure in 2006 [1]. HF has an annual mortality of 20%
per year after diagnosis, and its estimated economic burden
in the United Sates in 2009 was $37.2 billion [1].
Although HF manifests primarily with cardiopulmonary
symptoms, hyponatremia is very common in this patient
population.In fact, hyponatremia (variablydeﬁned as serum
sodium <1342–136mmol/L) is present in over 20% of
patients admitted to hospital with HF [2, 3]. Not only is it a
common occurrence, but it has repeatedly been shown to be
a marker of increased mortality in the HF population [3, 4].
As will be discussed in this paper, both the maladaptive
neurohormonal and renal changes as well as diuretic treat-
ment of HF contribute to the development of hyponatremia
[2–4]. In particular, the posterior pituitary hormone vaso-
pressin leads to renal water retention and hyponatremia. As
such, the recently developed vasopressin antagonists present
an attractive target for the management of hyponatremia in
HF [5].
2.Physiology ofWater Handling
To appreciate the pathophysiology of hyponatremia in HF,
it is important to understand the basic physiology of renal
salt and water handling. With the exception of psychogenic
polydipsia and low dietary solute intake, essentially all cases
oftruehyponatremia representafailuretoexcretemaximally
dilute urine. In the presence of normal renal function, this2 International Journal of Nephrology
failure is most often related to the action of vasopressin
(AVP).
AVP is a hormone synthesized in the supraoptic (SON)
and paraventricular nuclei of the hypothalamus and is
released from the posteriorpituitary [6].Itseﬀectsare multi-
ple and related to the aﬀected receptor (Table 1). Binding to
theV1a receptorleadsto vascularsmooth musclecontraction
[7]w h i l eV 2 receptor activation in the renal medulla leads
to free water reabsorption by the collecting duct. Binding
to V2 receptors, located on the basolateral membrane of the
cortical collecting duct cells, leads to increased aquaporin 2
(aqp-2)mRNAlevelsandtranslocation of aqp-2totheapical
membranes [6]. This increases tubular water permeability
and allows water to move from the tubule to the medullary
interstitium (down a concentration gradient), resulting in
net reabsorption of free water. This movement of water
is passive and relies upon a hypertonic renal medulla, the
generation of which is partly dependant on the activity of
the NKCC (sodium-potassium-2 chloride) channels in the
ascending loop of henle [8]. Absence of AVP activity (such
as in diabetes insipidus) leads to loss of high volume dilute
urine.
AVPreleaseismediatedbybothosmoticaswellascardiac
output and intravascular volume stimuli. Osmoreceptors
present in the SON are exceedingly sensitive to changes in
serum osmolality demonstrating alterations in AVP release
in response to a 1% ﬂuctuation in serum osmolality [9].
This sensitivity serves to keep serum osmolality tightly
controlled with a threshold for AVP release of approximately
280mOsm/Kg [9]. The nonosmotic stimuli for AVP release
consist of reductions in cardiac output, intravascular blood
volume, or blood pressure [9]. These stimuli, mediated
through high (aortic arch and carotid sinus) and low (left
atrial) pressure baroreceptors [10], enhance the secretion of
AVP for any given osmotic stimulus [9, 10]. In eﬀect, AVP
will be released at a lower plasma osmolality when decreased
intravascular volume, cardiac output or blood pressure are
detected.
Recently, AVP has been shown to be a potent and inde-
pendent regulator of the thiazide-sensitive Na(+)-Cl(−)
cotransporter (NCC) [11, 12]. This action is mediated
throughthe V2-receptor and itsclinical eﬀectsare, as yet, not
clear but implicate AVP in the handling of sodium as well as
water.
3.Pathophysiologyof Hyponatremiain
HeartFailure
In the normal physiologic state, alterations in serum osmo-
lality serve as the primary control for AVP release. However,
in conditions that lead to nonosmotic stimulation of AVP
release, these stimuli may take precedence resulting in the
acceptance of a lower serum osmolality [9]. Such is the case
inHFwhere adecreaseincardiacoutputleadstoacontinued
release AVP despite a reduction in osmolality, thus leading to
hyponatremia. Multiplestudieshavedemonstratedincreased
levels of AVP in HF leading accompanied by inadequate
inhibition when exposed to a decrease in serum osmolality
[13, 14]. Indeed, data in the Studies of Left Ventricular Dys-
function (SOLVD) show a progressive incremental increase
in AVP levels with worsening HF symptoms [15]. It has also
been shown that the density of AVP positive neurons in the
SONisincreasedbyasmuchas30%inpatientswithHF[16].
A number of other neurohormonal abnormalities con-
tributetoabnormalitiesinrenal sodium(Na)andwaterhan-
dling. Arterial underﬁlling (from decreased cardiac output)
detected by baroreceptors in the aortic arch, carotid sinus
and aﬀerent renal arterioles leads to activation of the sym-
pathetic nervous system (SNS) and the renin-angiotensin-
aldosterone system (RAAS) [2]. While the activation of
these systems acts to preserve systemic perfusion pressure in
patients with HF, it is a long-term maladaptive response that
leads to avid Na and water retention in multiple nephron
s e g m e n t s .T h i so v e r l o a do fN aa n dw a t e rm a yw o r s e n
cardiac function thus perpetuating the cycle of Na and water
retention. In addition, angiotensin II is a potent inhibitor
of thirst, which may lead to increased free water intake and
exacerbation of hyponatremia [17].
Reductions in glomerular ﬁltration rate are common
in patients with HF and can eventually lead to a reduced
capacity for water and Na excretion. It has been shown that
the ﬁltered load of Na decreases in parallel with declining
GFR in patients receiving diuretics [18]. While salt intake in
these patients exacerbates volume overload and HF, they are
also at risk of worsening hyponatremia with increased free
water intake.
Although a mainstay in the therapy of HF, diuretics
can also cause hyponatremia. These drugs increase Na and
water excretion thereby alleviating congestive symptoms and
theoretically helping to optimize cardiac contractility. It is
interestingtonotethatdespitetheirwidespreaduse,diuretics
havenotbeenshown toimprovesurvival inHFpatients[19].
Diuretics are prescribed in 85–100% of symptomatic and
16–35% asymptomatic patients with reduced left ventricular
function [20–22]. Loop diuretics are the most commonly
utilized diuretics and exert their salt wasting eﬀects by
inhibiting the NKCC channel in the thick ascending loop
of Henle. Other diuretics used frequently in HF include
thiazide diuretics and spironolactone. Thiazides inhibit the
Na-Cl cotransporter in the distal convoluted tubule while
spironolactone prevents activation of the mineralocorticoid
receptor on the principal cells of the cortical collecting duct.
Of these 3 classes, loop diuretics oﬀer the most potent
increase in Na and water excretion and thus are important
agents in the treatment of states of volume overload.
In the general population, diuretic-induced hypona-
tremia is very common, with thiazides accounting for the
63% of the cases of severe hyponatremia, loop diuretics
for 6%, and spironolactone for 1% [23]. The incidence of
hyponatremia with thiazide diuretics may be as high as
11% in the elderly [24]. Several features may contribute to
hyponatremia: (1) stimulation of AVP release secondary to
diuretic-induced volume contraction, (2) decrease in GFR
from intravascular volume contraction, (3) inhibition of
urinary dilutioncapacityduetointerferencewithNaabsorp-
tion in the distal segments, and (4) hypokalemia induced
intracellular shift of Na [24]. The thiazide eﬀect in the distalInternational Journal of Nephrology 3
Table 1: The actions of vasopressin and its receptors.
Receptor Location Action
V1a
Vascular smoothmuscle Vasoconstriction
Myocardial hypertrophy
Platelets Aggregation
Myometrium Uterine contraction
V1b Anterior pituitary Adrenocorticotropin hormonerelease
V2
Renal collecting tubule Induction of aquaporin-2
Free water absorption
Vascular endothelium Release of von Willebrand factor
Release of factor VIII
nephron accounts for its association with hyponatremia.
Conversely, loop diuretics may be spared from causing
hyponatremia by their eﬀect on the NKCC co-transporter,
which helps maintain the hypertonic medullary interstitium.
A reduction in the tonicity in this area decreases the gradient
for free water movement out of the tubules via aqp-2
channels and may therefore lessen the risk of hyponatremia
as compared to thiazides.
Owing to their disruption of the medullary concentra-
tion gradient, loop diuretics may actually lead to an increase
in Na in hyponatremic patients [25] .I f ,h o w e v e r ,t h e r e
is incomplete amelioration of the concentration gradient,
administration of loop diuretics can still cause hypona-
tremia. This likely relates to further stimulation of the
RAAS due to increased distal Na delivery thereby increasing
angiotensinII,awell-known stimulantofAVPsecretion[26].
4.EpidemiologyofHyponatremiain
HeartFailure
Given the number of neurohormonal changes in patients
with HF, it is not surprising that hyponatremia is very
common in this population. With Na and water retention
and decreased GFR from activation of the RAAS and SNS
in the context of increased AVP levels, continued intake of
hypotonic ﬂuids may lead to hyponatremia. Of all patients
admitted to hospital with a diagnosis of HF, 18–27% will
have hyponatremia (Na < 135mmol/L) on admission [27,
28].
Not only is hyponatremia common, it is also a strong
marker of increased morbidity and mortality in HF patients.
Lee and Packer [29] analyzed 30 clinical, hemodynamic, and
biochemical variables and their association with survival in
203 consecutive patients with severe HF. The most power-
ful predictor of cardiovascular mortality was pretreatment
serum Na, with hyponatremic patients having a substan-
tially shorter median survival than patients with a normal
serum Na (164 versus 373 days, P = .006). Similarly, in
theOutcomesofaProspectiveTrialofIntravenousMilrinone
for Exacerbations of Chronic Heart Failure (OPTIME-CHF)
study, both in hospital and 60-day mortality rates were
highestforpatientswiththelowestadmissionserumNa[27].
In the Organized Program to Initiate Lifesaving Treatment
in Hospitalized Patients with Heart Failure (OPTIMIZE-
HF) registry, patients with hyponatremia had signiﬁcantly
higher in-hospital and follow-up mortality rates and longer
hospital stays [30]. In this study, for each 3mmol/L decrease
in serum Na below 140mmol/L at admission, the risk of
in-hospital mortality and follow-up mortality increased by
19.5% and 10%, respectively. More recently, the importance
of persistent hyponatremia in HF patients was described
in a cohort of patients enrolled in the Evaluation Study of
Congestive Heart Failure and Pulmonary Artery Catheter-
ization Eﬀectivenes (ESCAPE) [31]. Hyponatremia in this
study was associated with higher 6-month mortality after
covariate adjustment (hazard ratio(HR), for each 3 mmol/L
decrease in serum Na, 1.23; 95% conﬁdence interval (CI),
1.05–1.43; P = .01). After controlling for baseline variables
and clinical response, patients with persistent hyponatremia
had an increased risk of all-cause mortality (31% versus
16%; HR, 1.82; P = .04), HF rehospitalization (62% versus
43%; HR, 1.52; P = .03), and death or rehospitalization
(73% versus 50%; HR, 1.54; P = .01) compared with
normonatremic patients.
It is unclear whether this increased mortality directly
related to hyponatremia or if the sodium abnormality is
a marker of a more severe underlying illness. It is likely
that it reﬂects a greater activation of the RAAS and SNS
with higher levels of AVP leading to increased mortality.
It has in fact been shown that patients with hyponatremia
have higher circulating levels of catecholamines, renin,
angiotensin, aldosterone, and AVP [32]. It is also feasible
that the presence of hyponatremia limits options in terms of
diuretic management and could potentially alter HF therapy
leading to diﬀerences in mortality. Moreover, hyponatremia
associated withdiuretic usemay beaccompaniedby multiple
other metabolic abnormalities such as hypokalemia and
hypomagnesemia that could increase mortality. In addition,
severe hyponatremia and its correction can respectively lead
to cerebral edema and the osmotic demyelination syndrome,
both of which are associated with high morbidity and
mortality.
5.Managementof Hyponatremiain
HeartFailure
Management of hyponatremia in heart failure demands a
multifaceted approach including optimization of cardiac
function (including prevention of volume overload and
neurohormonal blockade), preservation of renal function,4 International Journal of Nephrology
and maintenance of appropriate ﬂuid intake. In addition,
therelativelynewlydevelopedvasopressinantagonistspoten-
tially oﬀer an attractive therapeutic strategy for dealing with
hyponatremia in HF. Of utmost importance in any patient
with hyponatremia is to ensure adequate monitoring of
serumNa levels,asrapid changes in eitherdirection can have
dire consequences.
5.1. Optimization of Cardiac Function. Perhaps a simplistic
view of managing hyponatremia in HF is to ensure adequate
cardiac output. Ideally, this would reduce the stimulation of
baroreceptorsand lessen the activation ofthe SNSand RAAS
resulting in less renal avidity for Na and water and lower
levels of AVP.
While detailed management of HF is beyond the scope
of this paper, inhibition of the SNS and RAAS with β-
blockers (BB) and angiotensin converting enzyme inhibitors
(ACEi) or angiotensin receptor blockers (ARB) remain the
cornerstone of chronic HF management [33]. These agents
break the maladaptive cycle of neurohormonal activation
and via multiple mechanisms lead to improved preservation
of cardiac function [33]. They also lead to a reduction in left
ventricular afterload facilitating an improvement in cardiac
output. In addition, blockade of the aldosterone action
with spironolactone or eplerenonedecreases hospitalizations
and mortality in patients with New York Heart Association
(NYHA) class III and IV HF [34, 35]. In patients with
acuteexacerbationsofHF,afterload reductionwithACEiand
nitrates and utilization of positive inotropic agents may be
usedtoimprovecardiac output[36]thusin cr eas in gN alev els
in hyponatremic patients.
As previously discussed, diuretics remain a mainstay
of HF treatment and have complex eﬀects on serum Na
levels. Increasing Na and water loss can ease congestive
symptoms and, especially in combination with afterload
reduction and increased inotropy, can improve cardiac
outputin thevolume-overloadedpatient[36].Thisisusually
accomplished with loop diuretics, or a combination of loop
and thiazide diuretics, and can lead to increased Na levels in
the hyponatremic patient. It is important to note, however,
that excessive diuresis leads to hypovolemia, activation of the
S N Sa n dR A A S ,a n dd e c r e a s e dr e n a lf u n c t i o n .T h i se ﬀectcan
worsen cardiac function and lead to impaired renal Na and
water handling resulting in hyponatremia from increased
AVP release. In addition, a single bolus of furosemide has
been associated with an increase in plasma renin activity,
norepinephrine,andAVPleadingtoincreasedleftventricular
ﬁlling pressure and decreased stroke volume [37]. This
response to furosemide is potentially detrimental to the HF
patient.
Diuretic use has beenassociated with increased mortality
in both chronic and acute exacerbations of HF [38, 39]. It is
diﬃcult,however,todelineateacauseandeﬀectrelationship,
and despite a lack of evidence for their eﬀectiveness,
diuretics will likely remain an important component of
HF management for the foreseeable future. Due to the
complex physiology of HF, the eﬀect of loop diuretics
on serum Na can be diﬃcult to accurately predict thus
making frequent monitoring of serum Na very important.
In addition, nonpotassium sparing diuretics may lead to
signiﬁcant hypokalemia, hypomagnesemia, and decreased
renal function. It is therefore prudent to ensure adequate
monitoring of these parameters when using these agents.
5.2. Preservation of Renal Function. Patients with impaired
renal function have a decreased capacity for Na and water
excretion thus placing them at an increased risk of develop-
ing hyponatremia. Eﬀorts to maintain normal renal function
includingbloodpressure control,limiting useofnephrotoxic
medicationsandcontrastdye,andavoidingexcessivediuresis
may helpto limitthe risk ofhyponatremia. In patients whose
renal function is suﬃcientlypoortomaintainappropriateNa
and water balance, renal replacement therapy (hemodialysis
orperitonealdialysis)canremoveexcessiveNaandwaterand
maintain normal sodium levels.
5.3. Maintenance of Appropriate Fluid Intake. With high
levels of circulating AVP, HF patients will have a limited
capacity to excrete excess dietary free water. It thus follows
that HF patients with hyponatremia should limit dietary
water intake. The degree of limitation necessary will be
patient speciﬁc and dictatedby the degree ofneurohormonal
activation in each patient. Again, frequent monitoring will
help ensure an appropriate rise in serum Na in response to
the intervention.
5.4. Vasopressin Antagonists. Given the primary role of AVP
in free water retention and the development of hypona-
tremia, antagonism of AVP action would seem like a
rational therapeutic option in hyponatremic HF patients. As
vasopressin alsoleads tovasoconstriction andcardiomyocyte
hypertrophy [7], blocking its actions may have further
beneﬁcial eﬀects in HF.
A number of such drugs have been developed and target
either V2 receptors selectively or a combination of V2 or
V1a receptors. These agents lead to a selective loss in renal
free water losses termed aquaresis. To date, no studies have
shown a reduction in mortality with use of the vasopressor
antagonists in HF.
Preclinical studies in animals and humans showed that
administration of a V2 receptor antagonist leads to an
increase in free water excretion with little increased Na loss
and no compensatory activation of the RAAS [40–42]. These
positive results have led to a number of clinical trials of these
agents in HF patients.
Georghiade et al. compared tolvaptan to placebo in 254
NYHA class III or IV outpatients who continued to receive
standard HF therapy [43]. Patients received either 1 of 3 oral
doses of tolvaptan (30, 45, or 60mg/day) or placebo for a
total of 25 days. Although all patients treated with tolvaptan
had an increase in serum Na, the 28% who had baseline
had hyponatremia the greatest rise. 80% of tolvaptan-treated
patients with hyponatremia had normalization of serum
Na on day 1 compared to 40% of those receiving placebo.
These patientsalso had signiﬁcant reductionsin body weight
with an improvement in HF symptoms. A similar study in
319 patients randomized patients to 1 of 3 tolvaptan doses
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treatment for 60 days [28]. Patients in the tolvaptan group
had small increases in serum Na; the greatest rise in Na was
seen in the 21.3% of patients with baseline hyponatremia.
Tolvaptan-treated patients also had a signiﬁcant decrease in
body weight at 24 hours (median 2.05Kg in the highest dose
group) with no changes in heart rate, blood pressure, renal
function, or developmentof hypokalemia.
A larger study of 4133 patients assessed both- short
and long-term outcomes in patients admitted with acutely
decompensated HF [44, 45]. Patients were randomized
to receive Tolvaptan 30mg/day or placebo in addition to
standard HF care. Short-term outcomes at 7 days revealed
no diﬀerence in the primary outcome of global clinical
status.Similart othepr eviousstudies,ho w ev er ,thet ol vaptan
group did have a signiﬁcant decrease in body weight and
dyspnea. Of note, treatment with tolvaptan also led to
signiﬁcant increases in thirst, polyuria, and hypernatremia
(1.4%versus0%).The long-termfollow-up trialoveramean
of 9.9 months, found no diﬀerence in all-cause mortality,
cardiovascular death, or HF hospitalizations between the
groups. Improvements in dyspnea and serum Na were
maintained throughout followup with similar side eﬀects to
those seen in the short-term trial. A subgroup analysis of the
8% of the patients with baseline hyponatremia found serum
Na to be increased by 5.5mmol/L and 1.8mmol/L in the
tolvaptan and placebo groups, respectively.
Similar short-term outcomes of increased urine output
and serum sodium were found in patients with stable HF
receiving lixivaptan, another V2-receptor antagonist [46].
Ascending single doses of the drug were used and produced
a dose-dependent increase in urine output but no long-term
outcomes with this agent have been published.
Antagonism of the V1a receptors in addition to the V2
receptors has the added theoretical beneﬁt of decreasing
afterload by inhibiting AVP-mediated smooth muscle con-
traction. Conivaptan is one such agent with FDA approval
for treatment of hypervolemic hyponatremia. In a random-
ized, double-blind,placebo-controlled, multicenterstudy, 84
patients with hyponatremia were randomized to receive 1
of 2 doses of conivaptan (20mg bolus followed by 96 hour
infusion of either40 or 80mg/day) orplacebo, in addition to
standard HF treatments [47]. Both doses of conivaptan were
associated with signiﬁcant increases in serum Na. Na levels
increased by 6mmol/L or were normalized in 69% of the
40mg/day dose and 88.5% of the 80mg/day dose by day 4,
whereas only 20.7% of the placebo group achieved this goal.
Several studies of conivaptan in HF patients have yielded
similar results to those with V2-receptor antagonists [48–
50]. Recipients of conivaptan had increases in urine output
with decrease in left- and right-sided ﬁlling pressures and
had minimal side eﬀects. When compared with furosemide
alone, a combination of furosemide and conivaptan pro-
duced a dose-dependent increase in urine output [50]. In
addition, combination with higher doses of conivaptan (80
or120mg/day)ledtosmall butsigniﬁcant increases inserum
Na.
The precise role of vasopressin antagonists in the man-
agement of hyponatremic HF patients remains unclear.
While no eﬀectson mortality havebeenseen in clinicaltrials,
there are clear improvements in symptoms in the majority
of studies. To date, there have been no studies directly
comparing the eﬀects of V2 and combined V2/V1a-recpetor
antagonists which remains an interesting clinical question. It
isimportant tonotethatin all oftheaforementioned studies,
vasopressin antagonists have been used in conjunction with
usual HF treatment (including diuretics), and have not been
studied as a replacement for loop diuretics.
6.Conclusion
Hyponatremia in HF is a frequent occurrence related to
the activation of a multitude of neurohormonal pathways
including the SNS, RAAS, and particularly the increased
release of AVP. In addition to being common, hyponatremia
is associated with increased mortality in the HF population.
The treatment has traditionally consisted of RAAS and SNS
blockade in combination with loop and thiazide diuretics
and dietary water restriction. While this approach can be
eﬀective, diuretics have several detrimental metabolic side
eﬀectsandmaypotentiallyworsenhyponatremia andcardiac
function. Vasopressin antagonism represents a logical goal
in the management of hyponatremia in the HF population.
These agents have been shown to increase serum Na and
free water clearance and improve HF symptoms, but have
not yet been found to reduce long-term mortality. More
trials are necessary to deﬁne an exact role for the vasopressin
antagonists in HF patients.
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